A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.
暂无分享,去创建一个
F. Montorsi | P. Wiklund | T. Nyberg | C. Stief | B. Beyer | M. Graefen | T. Steuber | A. Briganti | P. Sooriakumaran | S. Dutton | M. Moschini | C. Gratzke | N. Suardi | B. Copsey | P. Hammerer | J. Karnes | L. Manka | Bethan Copsey
[1] R. Laing,et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2015, European urology.
[2] J. Fütterer,et al. Preferences in the management of high‐risk prostate cancer among urologists in Europe: results of a web‐based survey , 2015, BJU international.
[3] Michael Kerger,et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer , 2015, Nature Communications.
[4] M. Nykter,et al. The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.
[5] D. Pfister,et al. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. , 2015, The Journal of urology.
[6] C. Stief,et al. Role of Radical Prostatectomy in Clinically Non-Organ-Confined Prostate Cancer , 2014, Current Urology Reports.
[7] C. Stief,et al. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. , 2014, European urology.
[8] S. Boorjian,et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. , 2014, European urology.
[9] P. Schellhammer,et al. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. , 2014, European urology.
[10] S. McGuire,et al. Is treatment of the primary tumor in metastatic prostate cancer justified? , 2014, European urology.
[11] R. DiPaola,et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. Wiklund,et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes , 2014, BMJ : British Medical Journal.
[13] Ashutosh Tewari,et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. , 2012, European urology.
[14] A. Jemal,et al. International variation in prostate cancer incidence and mortality rates. , 2012, European urology.
[15] J. Steffens,et al. A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy. , 2011, The Journal of urology.
[16] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.
[17] Bethan Psaila,et al. The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.
[18] U. Roggenbuck,et al. Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. , 2008, The Journal of urology.
[19] P. Scardino,et al. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. , 2007, European urology.
[20] N. Munshi,et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.
[21] R. Sylvester,et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.
[22] M Bolla,et al. EAU guidelines on prostate cancer. , 2001, European urology.
[23] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.
[24] Wim Ceelen,et al. Surgery, wound healing, and metastasis: recent insights and clinical implications. , 2014, Critical reviews in oncology/hematology.
[25] T. H. van der Kwast,et al. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.
[26] E. Trimble,et al. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.